201. The effect of small molecules on nuclear-encoded translation diseases
- Author
-
Devorah Soiferman, Sarah Weissman, Ann Saada, and Oshrat Ayalon
- Subjects
Ribosomal Proteins ,Mitochondrial translation ,Mitochondrial disease ,Primary Cell Culture ,Respiratory chain ,Cytochrome-c Oxidase Deficiency ,Oxidative phosphorylation ,Biology ,medicine.disease_cause ,DNA, Mitochondrial ,Biochemistry ,Oxidative Phosphorylation ,Electron Transport ,Electron Transport Complex IV ,Mitochondrial Proteins ,Small Molecule Libraries ,medicine ,Humans ,Membrane Potential, Mitochondrial ,chemistry.chemical_classification ,tRNA Methyltransferases ,Reactive oxygen species ,Mutation ,Mitochondrial Myopathies ,General Medicine ,Fibroblasts ,Ribonucleotides ,Aminoimidazole Carboxamide ,Peptide Elongation Factor G ,medicine.disease ,Acetylcysteine ,Mitochondria ,Mitochondrial respiratory chain ,Gene Expression Regulation ,chemistry ,Protein Biosynthesis ,DNAJA3 ,Bezafibrate ,Reactive Oxygen Species - Abstract
The five complexes of the mitochondrial respiratory chain (MRC) supply most organs and tissues with ATP produced by oxidative phosphorylation (OXPHOS). Inherited mitochondrial diseases affecting OXPHOS dysfunction are heterogeneous; symptoms may present at any age and may affect a wide range of tissues, with many diseases giving rise to devastating multisystemic disorders resulting in neonatal death. Combined respiratory chain deficiency with normal complex II accounts for a third of all respiratory deficiencies; mutations in nuclear-encoded components of the mitochondrial translation machinery account for many cases. Although mutations have been identified in over 20 such genes and our understanding of the mitochondrial translation apparatus is increasing, to date no definitive cure for these disorders exists. We evaluated the effect of seven small molecules with reported therapeutic potential in fibroblasts of four patients with combined respiratory complex disorders, each harboring a known mutation in a different nuclear-encoded component of the mitochondrial translation machinery: EFTs, GFM1, MRPS22 and TRMU. Six mitochondrial parameters were screened as follows; growth in glucose-free medium, reactive oxygen species (ROS) production, ATP content, mitochondrial content, mitochondrial membrane potential and complex IV activity. It was clearly evident that each patient displayed an individual response and there was no universally beneficial compound. AICAR increased complex IV activity in GFM1 cells and increased ATP content in MRPS22 fibroblasts but was detrimental to TRMU, who benefitted from bezafibrate. Two antioxidants, ascorbate and N-acetylcysteine (NAC), significantly improved cell growth, ATP content and mitochondrial membrane potential and decreased levels of intracellular reactive oxygen species (ROS) in EFTs fibroblasts. This study presents an expanded repertoire of assays that can be performed using the microtiter screening system with a small number of patients' fibroblasts and highlights some therapeutic options while providing additional evidence for the importance of personalized medicine in mitochondrial disorders.
- Published
- 2014
- Full Text
- View/download PDF